+ Larger Font | + Smaller Font
Share

Welcome to Robin's Social Network

Be part of the community and join us today!

Hypercalcemia Treatment Market is Expected to Expand at an Impressive Rate by 2027

Hypercalcemia is a condition in which the calcium level in blood  increases above normal. It is a result of overactive parathyroid glands. Cancer, hereditary factors, and immobility are some of the causes of hypercalcemia. Moreover, people aged 50 year and above are at a higher risk of overactive parathyroid glands.

Increase in prevalence of hyperparathyroidism-related hypercalcemia is anticipated to drive the Hypercalcemia Treatment Market.

  • Key Drivers of Global Hypercalcemia Treatment Market

According to an article published in NCBI, hypercalcemia of malignancy accounted for approximately 20% of the total cancer patients during clinical course. In 2013, the prevalence of hypercalcemia of malignancy was 71,744 in U.S.

Increase in the number of patients with high incidence of multiple myeloma and cancer is anticipated to drive the global hypercalcemia treatment market. For instance, according to the America Cancer Society, in U.S., an estimated 32,110 multiple myeloma cases will be diagnosed and 12,960 deaths are expected in 2019.

According to an article published in JAMA Oncol, in 2016, an estimated 138,509 multiple myeloma cases were recorded with incidence rate of 2.1 per 100,000 people worldwide.

To obtain all-inclusive information on forecast analysis of Global Hypercalcemia Treatment Market, Request a PDF Brochure Here

According to an article published in Clinical Epidemiology, in the U.K., the prevalence of hypercalcemia of malignancy was between 0.24% and 0.81% during 2013- 2014.

Strategic development by key players is likely to fuel the growth of the hypercalcemia treatment market. For instance, in April 2018, Amgen Inc. received approval from the European Commission to expand the indication of XGEVA. This is used to treat patients with multiple myeloma and bone metastases from solid tumors. This has enabled the company to expand care for patients in Europe.

  • Research & Development and New Therapies to Offer Attractive Opportunities

Companies operating in the global hypercalcemia treatment market are engaged in the development of new products. For instance, the KHK7580 drug offered by Kyowa Kirin Co., Ltd. is in Phase 3 of the trial indicated for hypercalcemia in patient with primary hyperparathyroidism or parathyroid carcinoma. In April 2019, Kyowa Kirin Co., Ltd. supplemental application for KHK7580 in Japan. Thus, strong research and development will create lucrative opportunities in the near future.

New therapies, such as Denosumab (XGEVA), is emerging in second line therapies of hypercalcemia. It is offered by Amgen Inc. and available in the U. S.



on September 17 at 8:42

Comments (0)




Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2019 Robin's Social Network Content By Members. All Rights Reserved.